The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rudakova I.G.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo, Moskva

Vlasov P.N.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii", Moskva

Lipatova L.V.

Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva, Sankt-Peterburg

Voronkova K.V.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Lacosamide (vimpat). Prospects for clinical application

Authors:

Rudakova I.G., Vlasov P.N., Lipatova L.V., Voronkova K.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9): 147‑152

DOI: 10.17116/jnevro201711791147-152

Read: 8261 times

Download PDF (RU)
Contact the author
Table of contents

LACOSAMIDE (VIMPAT). PROSPECTS FOR CLINICAL APPLICATION
LACOSAMIDE (VIMPAT). PROSPECTS FOR CLINICAL APPLICATION

To cite this article:

Rudakova IG, Vlasov PN, Lipatova LV, Voronkova KV. Lacosamide (vimpat). Prospects for clinical application. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9):147‑152. (In Russ.)
https://doi.org/10.17116/jnevro201711791147-152

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Ototoxicity caused by anti-epileptic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):14-19
Pera­mpanel treatment in IQSEC2-associated epileptic ence­phalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):143-149
Febrile infe­ction-related epilepsy syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):34-40
Therapies for focal epilepsy asso­ciated with brain tumors. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):14-20
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Epileptic seizures in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):36-43
Abstract:

This article presents the review of the most significant studies of the efficacy and tolerability of lacosamide (LCM) in treatment of patients with focal epilepsy. The review includes the results of the main studies which preceded the official approval of LCM use in mono- and polytherapy. Results on the efficacy of LCM in long-term use and treatment retention in clinical practice, most effective LCM combinations, tolerability, an influence on cognitive and mental functions, advantages in treatment of elderly patients are presented. Characteristics of LCM in comparison with other sodium channel-blocking antiepileptic drugs and selection priorities are shown. The authors assess perspectives of further use of LCM in clinical practice.

Keywords:

epilepsy treatment
lacosamide
vimpat
sodium channel blockers
monotherapy
antiepileptic drugs
polytherapy

Authors:

Rudakova I.G.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo, Moskva

Vlasov P.N.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii", Moskva

Lipatova L.V.

Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva, Sankt-Peterburg

Voronkova K.V.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Close metadata

References:

  1. Covanis A, Guekht A, Li S, Mary Secco M, Shakir R, Perucca E. From global campaign to global commitment: The World Health Assembly’s Resolution on epilepsy. Epilepsia. 2015;56(11):1651-1657. https://doi.org/10.1111/epi.13192
  2. Karlov VA, Gekht AB, Guzeva VI, Lipatova LV, Bazilevich SN, Mkrtchan VR, Vlasov PN, Zhidkova IA, Mukhin KYu, Petrukhin AS, Lebedeva AV. Algorithms of mono- and polytherapy in clinical epileptology. Part 1. General principles of the choice of pharmacotherapy. Zh Nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116(6):109-114. http://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2016/6/ 1199772982016061109 (In Russ.).
  3. Карлов В.А., Гехт А.Б., Гузева В.И., Липатова Л.В., Базилевич С.Н., Мкртчан В.Р., Власов П.Н., Жидкова И.А., Мухин К.Ю., Петрухин А.С., Лебедева А.В. Алгоритмы моно- и политерапии в клинической эпилептологии. Часть 2. Особенности лечения отдельных групп пациентов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(7):120-129. https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2016/7/1199772982016071120/annotation
  4. Deckers C, Hekster YA, Keyser A, Van Lier HJJ, Meinardi H, Renier WO. Monotherapy vs Polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia. 2001;42(11):1387-1394. https://doi.org/10.1046/j.1528-1157.2001.30800.x
  5. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord. 2003;5(3):125-132. https://doi.org/10.3390/ph3082362
  6. Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia. 2005;46:858-877. https://doi.org/10.1111/j.1528-1167.2005.54904.x
  7. Curia G, Biagini G, Perucca E, Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-568. https://doi.org/10.2165/00023210-200923070-00002
  8. Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13(1):21-42. https://doi.org/10.1111/j.1527-3458.2007.00001.x
  9. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73(1):157-169. https://doi.org/10.1124/mol.107.039867
  10. Errington AC, Coyne L, Stöhr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology. 2006;50(8):1016-1029. https://doi.org/10.1016/j.neuropharm.2006.02.002
  11. Panayiotopoulos CP. Principles of therapy in the epilepsies. A Clinical Guide to Epileptic Syndromes and their Treatment. Springer London. 2010;173-235. https://doi.org/10.1007/978-1-84628-644-5_7
  12. Shandra A, Shandra P, Kaschenko O, Stoehr T. Synergism of lacosamide with established antiepileptic drugs in the 6 hz seizure model in mice. J Neurology. 2007;14(suppl 1):165-301. https://doi.org/10.1111/epi.12237
  13. Thomas D, Scharfenecker U, Nickel B, Doty P, Cawello W, Horstmann R. Low potential for drug-drug-interaction of lacosamide. Epilepsia. 2007; 48:321. https://doi.org/10.1016/j.ejpain.2007.03.211
  14. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 2007;73(1):1-52. https://doi.org/10.1016/j.eplepsyres.2006.10.008
  15. Jatuzis D, Biton V, Ben-Menachem E, Abou-Khalil B, Doty P, Rudd GD. SP667 Study Group. Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures. Epilepsia. 2005;46(8):70.
  16. Cawello W, Nickel B, Eggert-Formella A. Pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010;50(4):459-471. https://doi.org/10.1177/0091270009347675
  17. Cawello W, Bonn R. Pharmacokinetic Interaction Between Lacosamide and Valproic Acid in Healthy Volunteers. J Clin Pharmacol. 2012;52(11): 1739-1748. https://doi.org/10.1177/0091270011426875
  18. Chung S, Ben-Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, Hebert D, Isojarvi J, Doty P. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs. 2010;24(12):1041-1054. https://doi.org/10.2165/11586830-000000000-00000
  19. 19.Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled сlinical trials. Epilepsy & Behavior. 2015;52:119-127. https://doi.org/10.1016/j.yebeh.2015.09.006
  20. Villanueva V, Lopez-Gomariz E, Lopez-Trigo J, Palau J, Garcia M, Villarroya T, Bonet M, Santafe C. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy & Behavior. 2012;23(3):298-304. https://doi.org/10.1016/j.yebeh.2011.11.026
  21. Runge U, Arnold S, Brandt C, Reinhardt F, Kühn F, Isensee K, Ramirez F, Dedeken P, Lauterbach T, Noack-Rink M, Mayer T. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The VITOBA study. Epilepsia. 2015;56(12):1921-1930. https://doi.org/10.1111/epi.13224
  22. Villanueva V, Lopez FJ, Serratosa JM, González-Giraldez B, Campos D, Molins A, Uranga JR, Mauri JA, Javier Salas-Puig J, Toledo M, Sánchez-Alvarez JC, Moreno A, Serrano-Castro PJ, Saiz-Diaz RA, de la Aleja JG, de la Peña P, Asensio M. Control of seizyres in different stages of partial epilepsy: Laco-Exp, A Spanish retrospective Study of Lacosamide. Epilepsy & Behavior. 2013;29:349-356. https://doi.org/10.1016/j.yebeh.2013.07.024
  23. Villanueva V, Garcés M, López-Gomáriz E, Serratosa JM, González-Giráldez B, Parra J, Rodríguez-Uranga J, Rodríguez-Uranga M, González FJ, Bermejo P, Giner P, Castillo A, REALLY Study Group. Early Add-on Lacosamide in a Real-Life Setting: Results of the REALLY Study. Clin Drug Investig. 2015;35:121-131. https://doi.org/10.1007/s40261-014-0255-5
  24. Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, Werhahn KJ, Brock M. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine inpatients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. The Lancet Neurology. 2017;16(1):43-54. https://doi.org/10.1016/s1474-4422(16)30292-7
  25. Lebedeva AV, Burd SG, Beljaev OV, Vlasov PN, Dorofeeva MJu, Ismailov AM, Kissin MJa, Kovaleva IJu, Koroleva NJu, Lipatova LV, Muhin KJu, Solomatin JuV, Chervjakov A, Shikherimov RG, Pylaeva OA, Frejdkova NV. Russian experience with the use of lacosamide (vimpat) in the treatment of patients with uncontrolled focal epilepsy. Zh Nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116(9):74-81. (In Russ.). https://doi.org/10.17116/jnevro20161169274-81
  26. Rosenow F, Kelemen A, Ben-Menachem E, McShea C, Isojarvi J, Doty P. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand. 2016;133:136-144. https://doi.org/10.1111/ane.12451
  27. Novy J, Bartolini E, Bell GS, Duncan JS, Sander JW. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single-center evaluation. Epilepsy Res. 2013;106(1-2):250-256. https://doi.org/10.1016/j.eplepsyres.2013.05.002
  28. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54:11-27. https://doi.org/10.1111/j.1528-1167.2012.03671.x
  29. Wechsler RT, Li G, French J, O’Brien TJ, D’Cruz O, Williams P, Goodson R, Brock M; ALEX-MT Study Group. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical‐controlled, multicenter, double‐blind study. Epilepsia. 2014;55(7):1088-1098. https://doi.org/10.1111/epi.12681
  30. Ben-Menachem E. Medical management of refractory epilepsy: practical treatment with novel antiepileptic drugs. Epilepsia. 2014;55(1):3-8. https://doi.org/10.1111/epi.12494
  31. Власов П.Н., Шахабасова З.С., Филатова Н.В. Эпилепсия, впервые выявленная у пожилых пациентов: диагностика, дифференциальная диагностика, терапия. Фарматека. 2010;7:40-47. (In Russ.).
  32. Rosenfeld W, McShea C, Doty P. Evaluation of Long-Term Treatment with Lacosamide for Partial-Onset Seizures in the Elderly. 66th Annual Meeting of the American Epilepsy Society. San Diego, CA November 30 — December 4, 2012. https://doi.org/10.1212/wnl.78.1_meetingabstracts.p06.125
  33. Graf W, Kurzbuch K, Kerling F, Pauli E, Kasper BS, Stefan H. Cognitive and affective functions in adjunctive therapy with lacosamide. Epilepsia. 2011;52(suppl 6):224-225, abstract p738, IEC meeting 2011, Rome, Italy.
  34. Helmstaedter C, Witt JA. The longer-term cognitive effects of ajunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepcy & Behavior. 2013;26:182-187. https://doi.org/10.1016/j.yebeh.2012.11.052
  35. IJff DM, van Veenendaal TM, Majoie HJ, de Louw AJ, Jansen JF, Aldenkamp AP. Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy. Acta Neurol Scand. 2015;13:347-354. https://doi.org/10.1111/ane.12372
  36. Mukhin KYu, Mironov MB, Petrukhin AS. Epileptic syndromes. Diagnosis and treatment. Rukovodstvo dlya vrachei. M.: Sistemnye resheniya; 2014. (In Russ.).
  37. Genton P. When antiepileptic drug aggravate epilepsy. Brain Dev. 2000;22(2):75-80. https://doi.org/10.1016/s0387-7604(99)00113-8
  38. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, Mattson R, French JA, Perucca E, Tomson T. ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551-563. https://doi.org/10.1111/epi.12074
  39. Patsalos PN. Drug Interactions with the Newer Antiepileptic Drugs (AEDs). Part 1. Clin Pharmacokinet. 2013;52:927-966. https://doi.org/10.1007/s40262-013-0087-0
  40. Patsalos PN. Drug Interactions with the Newer Antiepileptic Drugs (AEDs). Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders. Clin Pharmacokinet. 2013;52:1045-1061. https://doi.org/10.1007/s40262-013-0088-z
  41. Pylaeva OA, Muhin KJu, Petruhin AS. The adverse events of antiepileptic therapy. M.: Granat; 2016. (In Russ.).
  42. Ramsay RE, Rovan J, Pryor FM. Special considerations in treating the elderly patients with epilepsy. Neurology. 2004;62(2):24-29. https://doi.org/10.1212/wnl.62.5_suppl_2.s24
  43. Bardai A, Blom M, van Noord C, Verhamme K, Sturkenboom M, Tan H. Sudden cardiac death is associated both with epilepsy and with use of antiepileptic medication. Heart. 2015;101(1):17-22. https://doi.org/10.1136/heartjnl-2014-305664
  44. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy research. 1999;37(1):81-87. https://doi.org/10.1016/S0920-1211(99)00039-X
  45. Guerreiro MM, Vigonius U, Pohlmann H, de Manreza ML, Fejerman N, Antoniuk SA, Moore A. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy research. 1997;27(3):205-213. https://doi.org/10.1016/S0920-1211(97)00025-9
  46. Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications, WHA Resolution, 26 May 2015 http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R20-ru.pdf, доступ декабрь2015
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.